|   | 
        
            
         | 
          | 
        
        
        
            | 
                
             | 
         
        
             | 
         
        
            
            
            
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    ³ª¼Òº¤¾ÆÄí¾î½º¾× 200ȸ    
                    
                 | 
               
              
                | 
                     Àü¹®ÀǾàǰ | »èÁ¦  
                        
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |  
                              
                                  | 
                                   | 
                               
            
            
                
            
            
              
            
                            
              
                                                     
            
            
   |  
  
    | 
      
     | 
   
   
     | 
   
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
   
  
    
      
	
	  
	     |  
	    
	      
	        
            
                | Çã°¡Á¤º¸ | 
                         
	         
	       | 
	     
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        659600041  
	    
	    
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
          
          
            \0 ¿ø/200ȸ/Åë(2018.03.01)(ÇöÀç¾à°¡) 
            \6,560 ¿ø/200ȸ/Åë(2017.02.01)(º¯°æÀü¾à°¡)
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
   
    | Á¦Ç°¼º»ó | 
    
      ¹é»ö Çöʾ×À¸·Î ºÐ¹«±â°¡ ÷ºÎµÊ   
      
	    [Á¦ÇüÁ¤º¸ È®ÀÎ]
     |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    Á¦Á¶¿øÀÇ Æ÷Àå´ÜÀ§¿¡ µû¸§ | 
   
  
  
  
  
  	
   
    | ÁÖ¼ººÐÄÚµå | 
    
      114531CSI  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
     | 
   
  
  
  
  
  	
   
    | ´ëÇ¥ÄÚµå | 
    8806596000408 | 
   
  
  
  
  
   
    | º¸°ü¹æ¹ý | 
    30¡ÉÀÌÇÏ º¸°ü, Â÷±¤, ±â¹Ð¿ë±â  | 
   
  
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
      
        [Á¶È¸]
     | 
      
  
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      ¾Ë·¹¸£±â¼º ºñ¿°, Ç÷°ü¿îµ¿¼º ºñ¿° 
      
      
     | 
   
  
  
  
  
  
  
  
  
    
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
     [󹿾à¾î] 
      ¼ºÀÎ ¹× 6¼¼ÀÌ»óÀÇ ¼Ò¾Æ : 
1ȸ µÎ ¹ø¾¿ ¾ç Äà¼Ó¿¡ °¢°¢ ºÐ¹«. 1ÀÏ 2ȸ (µðÇÁ·ÎÇÇ¿Â»ê º£Å¬·Î¸ÞŸ¼ÕÀ¸·Î 0.4¹Ð¸®±×¶÷ ÇØ´ç). ¶Ç´Â 1ȸ Çѹø¾¿ 1ÀÏ 3-4ȸ ¾ç Äà¼Ó¿¡ ºÐ¹«      
      	    
     | 
   
  
  
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    
      1) À¯È¿ÇÑ Ç×±ÕÁ¦°¡ ¾ø´Â °¨¿°Áõ, Àü½Å Áø±ÕÁõ ȯÀÚ 
2) ÀÌ ¾à¿¡ ´ëÇÏ¿© °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ 
3) ºñ(Þ¬)¼ö¼ú Èijª ¿Ü»ó, ºñ(Þ¬)Áß°Ý Ãµ°ø µîÀ» Ä¡·á¹Þ°í ÀÖÀ» ¶§ 
     | 
   
  
  
  
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
      ´ÙÀ½ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÏ¿© ±×·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª¸é ÀûÀýÇÑ Á¶Ä¡¸¦ ÃëÇÑ´Ù. 
1) ±¸° ¹× È£Èí±â : ¶§·Î ÀÎÈĵΠÁõ»ó(Àڰݰ¨, À̹°°¨), °¨¿°ÀÌ ³ªÅ¸³´Ù. 
   (ÀÌ °æ¿ì ºÐ¹«È½¼ö¸¦ ÁÙÀ̰ųª Åõ¿©¸¦ Áß´ÜÇÑ´Ù).  
2) ¼Òȱâ : ¶§·Î ±¸¿ª, ±¸Åä, Åä±â, ¼³»ç, ½Ä¿åºÎÁøÀÌ ³ªÅ¸³´Ù. 
3) ¼øÈ¯±â : ¶§·Î °íÇ÷¾ÐÀÌ ³ªÅ¸³´Ù. 
4) Á¤½Å‧½Å°æ : ¶§·Î µÎÅë, Çö±âÁõÀÌ ³ªÅ¸³´Ù. 
5) ºñ° : ºñÁõ»ó(Àڰݰ¨, ¼Ò¾ç°¨, °ÇÁ¶°¨, ºÒÄè°¨), ¶§·Î ºñÃâÇ÷, °¨¿°ÀÌ ³ªÅ¸³´Ù(ÀÌ °æ¿ì ºÐ¹«È½¼ö¸¦ ÁÙÀ̰ųª Åõ¿©¸¦ Áß´ÜÇÑ´Ù). ¶§·Î ÀÌÃë°¨, Èİ¢ÀåÇØ°¡ ÀϾ¸ç, Åõ¿© Á÷ÈÄ¿¡ Àçä±â ¹ßÀÛÀÌ ÀϾ ¼ö ÀÖ´Ù. ±ØÈ÷ µå¹® °æ¿ì·Î¼ ºÎ½ÅÇÇÁú È£¸£¸ó ¿¡¾î·ÎÁ¹Á¦Á¦ÀÇ ºñ°³» »ç¿ë½Ã ºñÁß°Ý Ãµ°øÀÌ º¸°íµÈ ÀûÀÌ ÀÖ´Ù. 
6) ´« : ºóµµºÒ¸íÀÇ ½Ã¾ßÈ帲ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
7) ±âŸ : ¶§·Î ±â°üÁö õ½ÄÀÌ ¹ßÇöµÇ°Å³ª ¾ÇȵȴÙ. 
          
     | 
   
  
  
    
   
    | ÀϹÝÀû ÁÖÀÇ | 
    1) õ½Ä¹ßÀÛÀÌ ¿À·¡ °è¼ÓµÈ »óÅ ȤÀº ±Þ°ÝÈ÷ ¾ÇȵÆÀ» ¶§´Â ¿øÄ¢ÀûÀ¸·Î »ç¿ëÀ» ±ÝÇÑ´Ù. 
2) Åõ¿©±â°£ Áß ºñ(Þ¬)Áõ»óÀÌ ¾ÇȵǴ °æ¿ì¿£ Ç×È÷½ºÅ¸¹ÎÁ¦ ȤÀº Àü½Å¼º ½ºÅ×·ÎÀ̵åÁ¦¸¦ ´Ü±â°£ º´¿ëÇϰí Áõ»ó °æ°¨¿¡ µû¶ó º´¿ë¾àÁ¦¸¦ ¼¼È÷ ÁÙÀδÙ. 
3) Àü½Å½ºÅ×·ÎÀ̵åÁ¦ÀÇ °¨·®Àº ÀÌ ¾à ÈíÀÔ °³½ÃÈÄ Áõ»óÀÌ ¾ÈÁ¤µÇ¸é ¼¼È÷ ÇàÇÑ´Ù. ÀÏ¹Ý ½ºÅ×·ÎÀ̵åÁ¦ÀÇ °¨·®¹ý¿¡ µû¸¥´Ù. 
4) Àå±â ȤÀº ´ë·®ÀÇ Àü½Å½ºÅ×·ÎÀ̵å¿ä¹ýÀ» ¹Þ´Â ȯÀÚÀÇ °æ¿ì ºÎ½ÅÇÇÁú ±â´ÉºÎÀüÀ» °í·ÁÇØ¾ß Çϸç, Àü½Å ½ºÅ×·ÎÀ̵åÁ¦¸¦ °¨·® ȤÀº Åõ¿© ÁßÁöÇÑ ÈÄ¿¡ ºÎ½ÅÇÇÁú ±â´É°Ë»ç¸¦ ÇÏ¿© ¿Ü»ó, ¼ö¼ú, ÁßÁõ °¨¿°Áõ µîÀÌ ÀϾ´ÂÁö ƯÈ÷ ÁÖÀÇÇϸç, ¶ÇÇÑ ÇÊ¿ä½Ã ÀϽÃÀûÀ¸·Î Àü½Å½ºÅ×·ÎÀ̵åÁ¦¸¦ Áõ·®ÇÑ´Ù. 
5) Àü½Å ½ºÅ×·ÎÀ̵åÁ¦¸¦ °¨·®Çϰųª Åõ¿©ÁßÁöÇÒ °æ¿ì ±â°üÁö õ½Ä ȤÀº ¶§·Î ½ÀÁø, µÎµå·¯±â, ÇöÈÆ, µ¿°è(ÔÑÌû), ±Çۨ, ¾ó±¼ Ȳö°Å¸², °á¸·¿°µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª°Å³ª ¾ÇȵǴ ¼ö°¡ ÀÖ´Ù(ÀÌ¿Í °°Àº Áõ»óÀÌ ³ªÅ¸³ª¸é ÀûÀýÇÑ Á¶Ä¡¸¦ ÃëÇÑ´Ù). 
6) ÁßÁõ ºñÈļº ºñ¿°À̳ª ºñ¿ëȯÀÚÀÇ °æ¿ì ºñ°³»¿¡¼ÀÇ ÀÛ¿ëÀ» È®½ÇÈ÷ Çϱâ À§ÇØ ±×·¯ÇÑ Áõ»óÀÌ ¾î´À Á¤µµ °¨¼ÒÇÒ ¶§±îÁö Ÿ¿ä¹ýÀ» º´ÇàÇÏÁö ¾Ê´Â °ÍÀÌ ÁÁ´Ù. 
7) ÀÌ ¾àÀº Áö¼ÓÀû È¿°ú°¡ È®ÀεǾúÀ¸¹Ç·Î ƯÈ÷ ¸¸¼ºÈ¯ÀÚ¿¡°Ô Àå±âÅõ¿©ÇÒ °æ¿ì¿¡´Â Áõ»ó °³¼±»óŰ¡ Áö¼ÓµÇ±â¸¸ ÇÑ´Ù¸é °¨·®Çϰųª Åõ¾àÀ» ÁßÁöÇÑ´Ù. 
8) ´ÙÀ½ ȯÀÚ¿¡°Ô´Â Åõ¿©¸¦ ¿øÄ¢ÀûÀ¸·Î ±ÝÇϳª ÇÊ¿äÇÑ °æ¿ì ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. : °áÇÙ¼º ȯÀÚ, È£Èí±â °¨¿°Áõ, °íÇ÷¾Ð, ´ç´¢º´, ¾È¾ÐÁõ°¡(³ì³»Àå) 
9) ½ÅÁßÅõ¿© : È£Èí±â ÀÌ¿ÜÀÇ °¨¿°Áõ ȯÀÚ(Ç×»ý¹°ÁúÀ» Åõ¿©ÇÏ´Â µî ÀûÀýÇÑ Á¶Ä¡¸¦ ÃëÇÑ´Ù). ¹Ýº¹¼º ºñÃâÇ÷ ȯÀÚ 
10) ÀÌ ¾àÀº ´ëºÎºÐÀÇ °èÀý ¾Ë·¹¸£±â¼º ºñ¿°À» Ä¡·áÇÒ ¼ö ÀÖÁö¸¸, ¿©¸§Ã¶ÀÇ °úµµÇÑ ¾Ë·¹¸£±â Ç׿ø¿¡ Á¢ÃËÇÑ °æ¿ì Àû´çÇÑ º¸Ãæ¿ä¹ý, ƯÈ÷ ¾ÈÁõ»ó ¿Ïȸ¦ À§ÇÑ Ã³Ä¡¸¦ ÇÏ´Â °ÍÀÌ ÁÁ´Ù. 
11) ÀÌ ¾àÀ» Áß´ÜÇÒ °æ¿ì ¸ÕÀú ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇØ¾ß ÇÑ´Ù. 
12) ƯÈ÷, ÀÌ ¾à Åõ¿©Áß¿¡ ¼öµÎ ¶Ç´Â È«¿ª¿¡ °¨¿°µÇ¸é, Ä¡¸íÀûÀÎ °æ°ú¿¡ À̸¦ ¼ö ÀÖÀ¸¹Ç·Î ´ÙÀ½ ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù. 
 (1) ÀÌ ¾à Åõ¿©Àü¿¡ ¼öµÎ ¶Ç´Â È«¿ªÀÇ º´·Â°ú ¿¹¹æÁ¢Á¾ÀÇ À¯¹«¸¦ È®ÀÎÇÑ´Ù. 
 (2) ¼öµÎ ¶Ç´Â È«¿ªÀÇ º´·ÂÀÌ ¾ø´Â ȯÀÚ¿¡ ´ëÇØ¼´Â ¼öµÎ ¶Ç´Â È«¿ª¿¡ÀÇ °¨¿°À» ÃÖ´ëÇÑ ¹æÁöÇÏ¿© ÃæºÐÇÑ ¹è·Á¿Í °üÂûÀ» ÇÑ´Ù. °¨¿°ÀÌ Àǽɽº·¯¿î °æ¿ì¿Í °¨¿°µÈ °æ¿ì¿¡´Â Áï½Ã ÁøÂûÀ» ¹Þ¾Æ ÁöµµÇϰí, ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù. 
 (3) ¼öµÎ ¶Ç´Â È«¿ªÀÇ º´·Â°ú ¿¹¹æÁ¢Á¾À» ¹ÞÀº ÀûÀÌ Àִ ȯÀÚ¿¡¼µµ ÀÌ ¾à Åõ¿©Áß¿¡ ¼öµÎ ¶Ç´Â È«¿ªÀÌ ³ªÅ¸³¯ °¡´É¼ºÀÌ ÀÖÀ¸¹Ç·Î À¯ÀÇÇÑ´Ù. 
13) Àü½Å ¹× ±¹¼Ò ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå »ç¿ëÀ¸·Î ½Ã·ÂÀå¾Ö°¡ º¸°íµÉ ¼ö ÀÖ´Ù. ȯÀÚ¿¡°Ô ½Ã¾ßÈ帲 ¶Ç´Â ±âŸ ½Ã·ÂÀå¾Ö¿Í °°Àº Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì, ȯÀÚ¸¦ ¾È°úÀǻ翡°Ô º¸³»¾î ¹é³»Àå, ³ì³»Àå ¶Ç´Â Àü½Å ¹× ±¹¼Ò ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå »ç¿ë ÈÄ º¸°íµÈ Áß½ÉÀå¾×¸Æ¶ô¸Á¸·º´(CSCR)°ú °°Àº Èñ±ÍÁúȯÀ» Æ÷ÇÔÇÏ¿© ¹ß»ý °¡´ÉÇÑ ¿øÀÎ Æò°¡¸¦ °í·ÁÇØ¾ß ÇÑ´Ù.  | 
   
  
  
  
  
  
  
   
    | ÀӺο¡ ´ëÇÑ Åõ¿© | 
    
      
	[ÀӺαݱ⠼ººÐ Á¶È¸]       
      µ¿¹°½ÇÇè¿¡¼ ÃÖ±âÇü¼º ÀÛ¿ëÀÌ º¸°íµÈ ÀûÀÌ ÀÖÀ¸¹Ç·Î ÀӺΠȤÀº Àӽа¡´É¼ºÀÌ ÀÖ´Â ºÎÀο¡°Ô´Â Ä¡·á»óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÜµÉ °æ¿ì¿¡¸¸ Åõ¿©ÇÑ´Ù.
     | 
   
  
  
  
  
  
  
  
   
    | ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© | 
    
      
       
      -¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© 
1) ÀÌ ¾àÀº ½ºÅ×·ÎÀ̵åÁ¦À̹ǷΠºñ(Þª)½ºÅ×·ÎÀ̵åÁ¦ ¾àÁ¦¿¡ ÀÇÇØ Áõ»óÀÌ °³¼±µÇÁö ¾Ê´Â °æ¿ì¿¡ »ç¿ëÇÑ´Ù. 
2) »ç¿ë½Ã¿¡´Â »ç¿ë¹ýÀ» ¿Ã¹Ù·Î ÁöµµÇÏ°í ±× °æ°ú¸¦ ÃæºÐÈ÷ °üÂûÇÑ´Ù. 
3) 12¼¼ ÀÌÇÏÀÇ À¯, ¼Ò¾Æ¿¡ ´ëÇÑ ¾ÈÀü¼ºÀº È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. ¼Ò¾Æ°¡ ÀÌ Á¦Ç°À» »ç¿ë½Ã ¼ºÀå·üÀÌ °¨¼ÒµÉ ¼ö ÀÖ´Ù. µû¶ó¼ Ä¡·á¿¡ À¯È¿ÇÑ ÃÖ¼Ò ¿ë·®À» »ç¿ëÇϰí ȯÀÚÀÇ ¼ºÀå·üÀ» Á¤±âÀûÀ¸·Î ¸ð´ÏÅ͸µ ÇÏ¿©¾ß ÇÑ´Ù.  | 
   
  
  
  
  
  
  
  
  
  
  
  
    
   
    | Àû¿ë»óÀÇ ÁÖÀÇ | 
    Àü¿ë ºÐ¹«±â¸¦ »ç¿ëÇÏ¿© ºÐ¹« ÈíÀÔÇÑ´Ù. | 
   
  
  
  
  
  
  		
  
  
   
    | º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ | 
    30¡ÉÀÌÇÏ º¸°ü, Â÷±¤, ±â¹Ð¿ë±â  | 
   
  	
  
  
    
   
    | ±âŸ | 
    ·¹¼¼¸£ÇÉ Á¦Á¦, ¾ËÆÄ¸ÞÄ¥µµÆÄ Á¦Á¦ µîÀÇ °¾ÐÁ¦¿¡¼´Â ºÎÀÛ¿ëÀ¸·Î¼ ºñÆó°¡ ³ªÅ¸³ª¹Ç·Î ÀÌ·¯ÇÑ °¾ÐÁ¦¸¦ º¹¿ëÇϰí ÀÖ´Â ¾Ë·¹¸£±â¼º ºñ¿° ȯÀÚ³ª Ç÷°ü¿îµ¿¼º ºñ¿° ȯÀÚ¿¡°Ô´Â ÀÌ ¾àÀ» Åõ¿©ÇÏ¿©µµ ºñÆóÁõ»ó¿¡ ´ëÇÑ Ä¡·áÈ¿°ú°¡ ³ªÅ¸³ªÁö ¾ÊÀ» ¼ö°¡ ÀÖÀ¸¹Ç·Î ÀÓ»ó °üÂûÀ» ÃæºÐÈ÷ ÇàÇÏ¸é¼ Åõ¿©ÇÑ´Ù. ´Ù·® Åõ¿©½Ã ½Ã»óÇϺÎ-³úÇϼöü-ºÎ½Å ±â´ÉÀÇ À§ÃàÀÌ ÀϾÙ. À̶§ °¨·®Çϸé 1-2ÀÏ ÈÄ È¸º¹µÈ´Ù. | 
   
  
  
  
  
   
    | Related FDA Approved Drug | 
    
       
     | 
      
  
  
      							
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¤º¸¿ä¾à | 
                 
	         
	       | 
	           	    
	     |  
	    | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ | 
                 
	         
	       | 
	           	    
	     |  
	    | 	 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¦Ç°Á¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | º¹¾àÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
  
   
    | Ãà¾àº¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Cµî±Þ 
				        	
					  
					
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  	
  
  
  
   
    | º¹¾à¶óº§ | 
    
    
    
      | À̹ÌÁö | 
      º¹¾à¼³¸í | 
     
    
    
        | 
      ¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. | 
     
    
       | 
     
    
     |  
    
      
	
	  
            | *  | 
	    º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. | 
	   
	  
            | *  | 
	    º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. | 
	   
	  
            | *  | 
	    ±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. | 
	   
	   
     |   
     | 
   
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ½É»çÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | ÇмúÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | Mechanism of Action | 
    
       Beclomethasone¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. 
     | 
   
  
   
    | Pharmacology | 
     
       Beclomethasone¿¡ ´ëÇÑ Pharmacology Á¤º¸ Beclomethasone, a synthetic halogenated glucocorticoid with antiinflammatory and vasoconstrictive effects, is used for treating steroid-dependent asthma, allergic or nonallergic rhinitis, or recurrent nasal polyps. 
     | 
   
  
   
    | Metabolism | 
    
       Beclomethasone¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available 
     | 
   
  
   
    | Protein Binding | 
    
       Beclomethasone¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 87% to albumin and transcortin 
     | 
   
  
   
    | Half-life | 
    
       Beclomethasone¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 2.8 hours 
     | 
   
  
   
    | Absorption | 
    
       Beclomethasone¿¡ ´ëÇÑ Absorption Á¤º¸ Mean peak plasma concentration was 88pg/ml at 0.5 hour 
     | 
   
  
   
    | Pharmacokinetics | 
    
       Beclomethasone DipropionateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
	- Ä¡·á È¿°ú : »ç¿ëÇÑÁö 1¡4ÁÖ ³»¿¡ ¹ßÇö
	
 -  ÈíÀÔ(inhalation)
	
		- Èí¼ö : ½±°Ô Èí¼öµÈ´Ù. Èí¼öµÇ±â Àü¿¡ ÆóÀÇ esterases¿¡ ÀÇÇØ ºü¸£°Ô °¡¼öºÐÇØµÈ´Ù.
		
 - ºÐÆ÷ : Åõ¿©·®ÀÇ 10¡25%°¡ ±âµµ¿¡ µµ´Þ
   
	 -  °æ±¸
	
		- Èí¼ö :  90%
		
 - ºÐÆ÷ : À¯ÁóÀ¸·Î ºÐºñµÈ´Ù.
		
 - ´Ü¹é°áÇÕ : 87%
		
 - ´ë»ç : °£¿¡¼ ´ë»çµÈ´Ù.
		
 - ¹Ý°¨±â : Ãʱ⠹ݰ¨±â : 3½Ã°£, ¸»±â(terminal) ¹Ý°¨±â : 15½Ã°£ 
		
 - ¼Ò½Ç : ½Å¹è¼³
    
     | 
   
  
   
    | Biotransformation | 
    
       Beclomethasone¿¡ ´ëÇÑ Biotransformation Á¤º¸ Metabolism mediated via esterase enzymes that are found in most tissues. Undergoes rapid and extensive conversion to beclomenthasone-17-monopropionate (17-BMP) during absorption 
     | 
   
  
   
    | Toxicity | 
    
       Beclomethasone¿¡ ´ëÇÑ Toxicity Á¤º¸ The acute toxicity of beclomethasone dipropionate is low. The only harmful effect that follows inhalation of large amounts of the drug over a short period of time is suppression of hypothalamic-pituitary-adrenal (HPA) function. Chronic: The excessive use of beclomethasone dipropionate over a long period could lead to adrenal suppression. 
     | 
   
  
   
    | Drug Interactions | 
    
       Beclomethasone¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Food Interaction | 
    
       Beclomethasone¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Beclomethasone¿¡ ´ëÇÑ Description Á¤º¸ An anti-inflammatory, synthetic glucocorticoid. It is used topically as an anti-inflammatory agent and in aerosol form for the treatment of asthma. [PubChem] 
     | 
   
  
   
    | Drug Category | 
    
       Beclomethasone¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Asthmatic AgentsAnti-inflammatory AgentsAntiarrhythmic AgentsCorticosteroidsGlucocorticoids 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Beclomethasone¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(O)C(=O)CO 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Beclomethasone¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO 
     | 
   
  
   
    | InChI Identifier | 
    
       Beclomethasone¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C22H29ClO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Beclomethasone¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one 
     | 
   
    
  |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ | 
                             
	         
	       | 
	           	  
       |  
	     |  
	   
	     	
 
  | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-12-02
              
 
              - 
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
                    
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
  
  |  
             
             | 
         
         
         | 
         |